If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 171 - 180 of 279
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Objective
Study of IMVT-1402 Treatment in Adult Participants with CIDP
Protocol No
NEURO-IMVT-1402-2401
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Protocol No
NEURO-TG-ENHANCE
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Objective
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in
Advanced KRAS Mutated Cholangiocarcinoma
Advanced KRAS Mutated Cholangiocarcinoma
Protocol No
GENFIT-GNS561-222-1
Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged
Objective
A Phase III study comparing the use investigational drug ziftomenib to intensive chemotherapy and and the use of ziftomenib as maintenance therapy following intensive chemotherapy.
Protocol No
KURA-KO-MEN-017
Categories
Frontline T-Cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification Therapy in Multiple Myeloma
Objective
Study of t-cell engager vs. stem cell transplant and MRD-guided therapy in multiple myeloma
Protocol No
SCRI-FASTER-MM195
Categories
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Objective
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Protocol No
STEMLINE-MEN2312-01
Categories
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for
Objective
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/​or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Protocol No
NEOGENE-NT-175-201
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Objective
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for patients with early-stage oral cavity cancer.
Protocol No
NRG-HN006
Categories
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Objective
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Protocol No
ALLIANCE-A041501-ALL
Categories
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Objective
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Protocol No
DERM-INCYTE-INCB018424-325
Categories